About the Phase 2 DisTinGuish Study
Trial Name: A Phase 2a, Multicenter, Open-Label Study of DKN-01 in Combination With Tislelizumab ± Chemotherapy as First-Line or Second-Line Therapy in Adult Patients With Inoperable, Locally Advanced or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma (DisTinGuish))
ClinicalTrials.gov Identifier: NCT04363801
Sponsor: Leap Therapeutics, Inc. (Collaborator: BeiGene).
Recruitment Contact: Cynthia Sirard, MD 617-714-0357 CSirard@leaptx.com
Completion Date: June 2023